For an analyst to step out of his field and suggest that Amgen or Viking or anyone else would combine drugs solely on the basis that they're on a similar dosing sequence is ludicrous.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.